PFE Stock Recent News

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court.

Both JNJ & PFE expect their sales and profits to improve in 2025.

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (PFE 0.77%) and Moderna (MRNA 2.21%). These two vaccine makers made small fortunes thanks to their work in this space.

These overlooked stocks could be the next big AI winners—and they pay you to wait. Forget Nvidia: This is where the real AI-fueled upside may be hiding. Massive AI gains without the hype—discover income-rich stocks flying under the radar.

Pfizer's (PFE 0.77%) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022.

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.

In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.

Companies with attractive valuations, strong competitive advantages, and sustainable dividend growth can help investors steadily increase wealth while reducing risk. The selection process of my top 10 high dividend yield companies for April 2025 involves analyzing financial ratios, competitive advantages, valuations, and ensuring diversification across industries and countries. The 10 selected companies offer investors an Average Dividend Yield [FWD] of 5.30% and a 5-Year Average Dividend Growth Rate [CAGR] of 8.33%, allowing investors to combine income and growth.

Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.

Institutional Shareholder Services is recommending Pfizer's investors to reject a management proposal on annual compensation for CEO Albert Bourla and other executives, the proxy adviser said on Wednesday.